InsidersTradesSigma
Follow the 10x Genomics, Inc. stock price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, 10x Genomics, Inc. has published 275 insider filings. Market capitalisation: €8.1bn. The latest transaction was disclosed on 3 September 2026 (Don). Among the most active insiders: Saxonov Serge. The full history is free.
275
Insider Decl.
n/a
Thresholds
€436,657
3 ops.
Buy Volume
€18m
132 ops.
Sell Volume
47Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 21,813 of 29,062 companies
34.5
score / 100
Value39
Quality30
FCF yld1.6%
Earn yld-0.5%
EV/EBITDA·
ROE-9.4%
Gross mgn69%
Net mgn-6.8%
Debt/EBITDA21.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 September 2026
Declarations275 total
100 shares0Class A Common StockSEC:0001610717-26-000396:0
20,000 shares@ US$61.75230.015% mcap16.0% of flowClass A commonSEC144:0001957799-26-000170
3,500 shares@ US$63.02290.0026% mcap2.5% of flowClass A Common StockSEC:0001610717-26-000393:0
6,494 shares@ US$63.97680.0049% mcap4.8% of flowClass A Common StockSEC:0001610717-26-000393:1
492 shares@ US$64.74650.0004% mcap0.4% of flowClass A Common StockSEC:0001610717-26-000393:2
35,486 shares@ US$62.18380.026% mcap100.0% of flowClass A CommonSEC144:0001968582-26-000886
13,818 shares@ US$63.02360.010% mcap18.0% of flowClass A Common StockSEC:0001610717-26-000390:0
561 shares@ US$62.72590.0004% mcap25.0% of flowClass A Common StockSEC:0001610717-26-000389:0
1,646 shares@ US$63.96640.0012% mcap75.0% of flowClass A Common StockSEC:0001610717-26-000389:1
17,166 shares@ US$63.0230.013% mcap33.1% of flowClass A Common StockSEC:0001610717-26-000391:0
18,545 shares@ US$63.02370.014% mcap14.5% of flowClass A Common StockSEC:0001610717-26-000392:0
13,373 shares@ US$65.120.010% mcap21.9% of flowCommon StockSEC144:0001786391-26-000003
17,948 shares@ US$65.120.014% mcap17.0% of flowCommon StockSEC144:0001786720-26-000003
2,207 shares@ US$65.120.0017% mcap43.7% of flowClass A CommonSEC144:0001968582-26-000871
16,614 shares@ US$65.120.013% mcap49.4% of flowCommon StockSEC144:0001971187-26-000004
4,000 shares0Class A Common StockSEC:0001610717-26-000386:0
5,278 shares@ US$57.290.0042% mcap52.5% of flowClass A Common StockSEC:0001610717-26-000359:0
2,273 shares@ US$57.150.0018% mcap22.5% of flowClass A Common StockSEC:0001610717-26-000359:1
2,273 shares@ US$57.150.0017% mcap30.0% of flowCommonSEC144:0001950047-26-008153
5,278 shares@ US$57.290.0040% mcap100.0% of flowCommonSEC144:0001950047-26-008060
3,000 shares@ US$58.7250.0023% mcap2.7% of flowClass A Common StockSEC:0001610717-26-000358:1
17,000 shares@ US$57.58120.013% mcap15.1% of flowClass A Common StockSEC:0001610717-26-000358:0
20,000 shares@ US$57.75160.017% mcap21.7% of flowClass A commonSEC144:0001957799-26-000152
8,527 sharesClass A Common StockSEC:0001610717-26-000293:0
9,991 sharesClass A Common StockSEC:0001610717-26-000293:1
25 of 275 declarations
关于 10x Genomics, Inc.
10x Genomics, Inc. 是一家总部位于美国加利福尼亚州普莱森顿的生命科学工具公司，在纳斯达克上市，股票代码为TXG。对于法国、比利时和瑞士的投资者而言，该公司在医疗保健和研究工具领域占据了一个有吸引力的利基市场：它提供帮助科学家以单个细胞的分辨率和组织的空间背景研究生物学的技术。10x Genomics由Serge Saxonov和Ben Hindson于2012年创立，已成为单细胞和空间生物学领域最受认可的品牌之一，尤其是在学术和转化研究环境中。([10xgenomics.com](https://www.10xgenomics.com/company/?utm_source=openai)) 该公司的商业模式围绕用于研究目的的仪器、耗材、试剂、软件和工作流程构建，以对细胞和组织进行分析。其核心平台包括用于单细胞分析的Chromium、用于空间转录组学的Visium和用于原位分析的Xenium。这些产品旨在为肿瘤学、免疫学、神经科学和发育生物学等领域生成高分辨率的生物数据。实际上，这使得10x Genomics面临的是研究和发现支出周期，而不是常规临床诊断，这对于评估需求波动和采用速度的投资者来说是一个重要考量。([10xgenomics.com](https://www.10xgenomics.com/company/?utm_source=openai)) 从竞争角度来看，10x Genomics在数据质量、工作流程整合和广泛的科学生态系统方面建立了强大的声誉。该公司强调其拥有超过10,000篇出版物、庞大的仪器装机量以及遍布美国、欧洲和亚洲（包括荷兰、台湾、中国和新加坡等地）的全球业务。这种国际影响力支持了其商业覆盖范围，并帮助公司服务全球主要研究机构。([10xgenomics.com](https://www.10xgenomics.com/company/?utm_source=openai)) 近期新闻主要集中在产品创新和产品组合扩展上。2024年，10x Genomics在其所有三个平台推出了主要新产品，包括Chromium GEM-X、Visium HD和Xenium Prime 5K。在2025年2月的财报发布中，该公司报告2024财年收入为$610.8 million，年末现金和有价证券为$393.4 million，同时指出宏观环境充满挑战。该公司还宣布与Chan Zuckerberg Initiative和Ultima Genomics合作开展“十亿细胞项目”（Billion Cells Project），强调其在构建大规模生物数据集和推进人工智能生物学方面的战略作用。([sec.gov](https://www.sec.gov/Archives/edgar/data/1770787/000177078725000011/txg-fy2024earningsreleasee.htm?utm_source=openai))
